A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility

Anesthesia and Analgesia

Volumn 90, Issue 1, 2000, Pages 200-205

  Baur, C P ^a   Bellon, L ^b   Felleiter, P ^e   Fiege, M ^c   Fricker, R ^e   Glahn, K ^e   Heffron, J J A ^d   Herrmann Frank, A ^a   Jurkat Rott, K ^a   Klingler, W ^a   Lehane, M ^d   ORding H ^e   Tegazzin, V ^b   Wappler, F ^c   Georgieff, M ^a   Lehmann Horn, F ^a  

^a UNIVERSITY OF ULM   (Germany)

^b S ANTONIO HOSPITAL   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CHLOROCRESOL; HALOTHANE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; MULTICENTER STUDY; MUSCLE CONTRACTURE; PRIORITY JOURNAL;

EID: 17144445400     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200001000-00040     Document Type: Article

References (28)

1. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992;256:789-94.
2. 2+ release channels. Am J Med 1998;104: 470-86.
3. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56:254-62.
4. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility: The European Malignant Hyperpyrexia Group. Br J Anaesth 1984;56:1267-9.
5. Larach MG. Standardization of the caffeine halothane muscle contracture test: North American Malignant Hyperthermia Group. Anesth Analg 1989;69:511-5.
6. Gronert GA, Antognini JF. Malignant hyperthermia, anesthesia. Miller RD, ed. New York: Churchill Livingstone, 1994:1075-93.
7. Ørding H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European Malignant Hyperpyrexia Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand, 1997;41:955-66.
8. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American malignant hyperthermia registry. Anesthesiology 1998;88:579-88.
9. Denborough M. Malignant hyperthermia. Lancet 1998;352: 1131-6.
10. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br J Anaesth 1991;66:611-3.
11. Hopkins PM, Hartung E, Wappler F, and the European Malignant Hyperthermia Group. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth 1998;80:389-94.
12. Lenzen C, Roewer N, Wappler F, et al. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. Br J Anaesth 1993;71:242-6.
13. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993;79:5-9.
14. Herrmann-Frank A, Richter M, Lehmann-Horn F. 4-Chlorom-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 1996;52:149-55.
15. 2+ release. Mol Pharmacol 1993;44:1192-201.
16. Herrmann-Frank A, Richter M, Sarközi S, et al. 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim Biophys Acta 1996;1289:31-40.
17. 2+ channel. Anesthesiology 1996;84:1380-5.
18. Gilly H, Musat I, Fricker R, et al. Classification of malignant hyperthermia-equivocal patients by 4-chloro-m-cresol. Anesth Analg 1997;85:149-54.
19. Ørding H, Glahn K, Gardi T, Bendixen T. 4-chloro-m-cresol test: a possible supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol Scand 1997;41:967-72.
20. Wappler F, Scholz J, v. Richthofen V, et al. 4-Chloro-m-Cresol induziert kontrakturen an skelettmuskelpräparaten von patienten mit disposition zu maligner hyperthermie. Anästhesiol Intensivmed Notfallmed Schmerzther 1997;32:541-8.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
22. Youden W. Index for rating diagnostic tests. Cancer 1950;3:32-5.
23. Mickelson JR, Gallant EM, Litterer LA, et al. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988;263:9310-5.
24. Wappler F, Roewer N, Kochling A, et al. Fulminant malignant hyperthermia associated with ketoacidotic diabetic coma. Intensive Care Med 1996;22:809-12.
25. Iaizzo PA, Johnson BA, Nagao K, Gallagher WJ. 4-chloro-m-cresol triggers malignant hyperthermia in susceptible swine at doses greatly exceeding those found in drug preparations. Anesthesiology 1999;90:1723-32.
26. Wappler F, Scholz J, Fiege M, et al. 4-Chloro-m-cresol is a trigger of malignant hyperthermia in susceptible swine. Anesthesiology 1999;90:1733-40.
27. Brandt A, Schleithoff L, Jurkat-Rott K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in-vitro contracture test. Hum Mol Genet 1999;8:2055-62.
28. Manning BM, Quane KA, Ørding H, et al. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 1998;62:599-609.